Enter the first few characters of Company and click 'Go'

Alembic Ltd. Company History and Annual Growth Details

YEAR EVENTS
1907 - The Company was Incorporated at Vadodara. The Company
manufacture chemicals, pharmaceuticals, injections, penicillin,
antibiotics, sulphuric acid, superphosphate and other
fertilisers, generating electricity, manufacture of electronic
items, running of hospitals and health care units, etc.

1938 - The authorised capital was Rs 20 lakhs divided into 10,000-6 1/4%
preference shares of Rs 100 each and 10,000 No. of equity shares
of Rs 100 each. 5,000 preference shares and all equity shares
were issued and subscribed.

1942 - 5,000-6% preference shares were issued and subscribed.

1944 - The authorised capital was increased to Rs 50 lakhs by the
creation of 30,000 shares of Rs 100 each out of which 3,000
shares were classified as equity shares and issued to the
shareholders in the proportion 3:10.

1946 - The Company issued 2,000 No. of equity shares as rights at a
premium of Rs 150 per share in the proportion 2:13.

1947 - 5,000 unclassified shares were converted into equity, shares and
they were issued as rights at a premium of Rs 150 per share in
the proportion 1:3.

1948 - 5,000 unclassified shares were converted into equity shares and
issued as bonus in the proportion 1:4.

1949 - The authorised capital was increased to Rs 1 crore by creation of
5,000-6% third preference shares of Rs 100 each and 45,000
unclassified shares of Rs 100 each. Further 7,000 unclassified
shares were converted into equity shares and issued as bonus in
the proportion of 2:3 irrespective of class.

1958 - The authorised, issued and paid-up capital stood at Rs 100,00,000
and Rs 80,00,000 respectively as at 31st December.

1959 - 20,000 Right Equity shares offered at par in prop. 1:4 to all
classes. In 1961, 10,000 Right Equity shares offered at par in
prop. 1:1 to classes.

1962 - 9,500 Bonus equity shares issued in prop; 1:10, 40,000 Right
Equity shares offered at a prem. of Rs 30 per share in the prop.
4:11 irrespective of class.

1966 - In Dec. 48,167 Bonus Equity shares issued in prop. 1:3. 12,278
No. of equity shares issued without payment in cash to members
of Alembic Distributors Ltd., Mumbai and Alembic distributing
Agency, Bangalore on their merger.

1967 - The amalgamation on Alembic Distributors, Ltd., with the Company
from 1st January, was sanctioned by the High Courts of Ahmedabad
and Mumbai. The Scheme of Amalgamation of Neomer Ltd. with the
Company from the appointed date 1.1.1983 was approved by the High
Court of Gujarat by its Order dated 12.9.1986.

1968 - 25,080 Right Equity shares issued at par in prop. 5:41.

- In March 1971, 57,487 Right Equity shares issued at par in the
prop. 1:5.

1977 - 6 1/4% Pref. and 6% III Pref. shares converted to 9% redeemable
Pref. shares from 1.1.1976. 5,000-5% Pref. shares redeemed at
Rs 105 per shares on 1.1.1977.

1979 - The Company issued 75,000 secured debentures of Rs 100 each as
rights to augment the resources of working capital.

1980 - Redeemed 1,000 Pref. shares each on 1.1.1978, 1.1.1979,
1.11.1980, 1.1.1981, 1.1.1982 and 1.1.1983.

1985 - 2,000 Pref. shares redeemed. 66,900 No. Equity shares allotted
without payment in cash to the shareholders of Neomer, Ltd. on
its merger. 2,000 Pref. shares redeemed.

1989 - A variety of new products were introduced under group Feed
Supplements and Tonics which were well received in the market.

- The Panpharm Division was started at village Panelav in
Panchmahal district of Gujarat State to undertake manufacture of
formulations.

1990 - A new quinolone antibacterial drug "Ciprofloxacin" was introduced
in the market.

- The Veterinary Division introduced certain new farm products like
ascal, ruman bolus etc. during the year.

- New products such as ginseng preparation and zinc and vitamin-B
complex preparations were introduced in the market.

- 100,000-14% non-convertible debentures were issued. These
debentures are redeemable in three yearly instalments commencing
from 11th May, 1995 with redemption premium of 5% payable along
with the last instalment.

1991 - As a result of the research and development activities, the
company developed Roxithronycin, a newer generation bulk drug.

1992 - The veterinary division introduced Cloxacillin Amoxicillin
injections.

- Introduction of Cloxacillin Amoxicillin injection in the market.

1993 - The Expansion of Penicillin capacity to 1000 MMU together with
integrated effluent treatment plant was undertaken and series of
steps were taken to instal diesel engine driven compressors for
constant air supply etc.

- The erstwhile Neomer, Ltd. had a licensed capacity to manufacture
6000 mt. polypropylene staple fibre. In addition to this, it was
registered with D.G.T.D. for the manufacture of 1000 mt. per
annum. of polypropylene multifilament yarn.

- Under the broad banding policy, Neomer had obtained permission to
manufacture other synthetic filament yarn i.e. polyester and
nylon yarn including industrial yarn/tyre cord.

- The company introduced a revolutionary antibiotic Azithromycin
which is used in tissue directed antibiotic therapy.

1995 - With a view to facing this eventuality the company proposed to
install gas turbine based captive Co-generations Power Unit at a
total outlay of Rs 25 crores.

- Two large pencillin fermentors were installed and commissioned.

- "Algen, Ltd." is a subsidiary of the Company. As at 31st Dec.
10,007 No. of equity shares out of 10,013 No. of equity shares of
Rs 10/- each issued by the subsidiary were held by the Company.

- 164,732 No. of equity shares of Rs 100 each at a premium of Rs
850/- per share issued to the shareholders on rights basis.

1996 - 10,00,000 Pref. shares allotted on preferential basis.

1997 - The performance of the pharmaceutical division was affected by
Governmental basis imposed on scrip to pencillin formulation
which affected the major brand of the company.

- The Company introduced Nimegesic Gel an important topical item.
The Company introduced Rorid liquid for paediatric use, a ready
made suspension of Roxithromycin. The Company strengthened its
position by the introduction of Clarithro and basic manufacture
of clarithromycin.

- The company installed Peniccillin - Gas 600 m.m.u. per annum and
Erythromycin 100 tpa. Also, a second line of extraction facility
for erythromycin was installed.

- The Alembic Herbals veterinary, a new division of veterinary
business was launched in June.

- The Company issued 10,00,000-16% redeemable non-convertible
cumulative preference shares of Rs 100 each. These are
redeemable at par on 11.2.1999.

- The Company has expanded its reach in the fastest growing analgesics and
anti-inflammatory segment with the launch of new molecules Rofecoxib and
Celecoxib.

2000 - The Company has launched Glycodin Activ Cold & Flu Tablets.

2001 - The Company has launched its version of sildenafil citrate, under the brand name
`Asigra'. The pill for erectile dysfunction is in two dosage forms of 25 mg and 50 mg
as against three by most of the other players.

- The Company has launched a new OTC brand, Glycodin Activ cold and flu tablets.

2002

-Gujarat High court sanctions for the merger of Bulk Drug unit of M/s Darshak Ltd with the company.

-Enters into an in-licensing pact with Euroresearch for introducing Gelfix Collagen dressing sponge pads in the country.

-Appoints Mr Nitin Jaywant as the President, Active Pharmaceutical Ingredients division.

-Floats a new division called 'SynX' to cater to patients suffering from condition called Syndrome X .

-Enters into a research pact with Chiron Corporation of US for contract research.

-Gets approval from DCGI to manufacture and market Cefetamet Pivoxil tablets.

-Ties up with Italian Pharma company, Euroresearch to bring its products to India.

2003

-Launches 4th generation injectable Cephalosporin Cefepime under the brand name of Cepime.

-Allots equity shares to the shareholders of M/s Darshak Ltd as per the scheme of demerger.

-Acquires brand and trade mark rights of obstretical care drug Yutopar from Solvay Pharmaceuticals BV, Netherlands.

-Launches new division for research and development services, BioArc Research Solutions.

-Forays into speciality therapeutics segment.

-Signs agreement with two MNC companies for R & D division.

-Lines up a rights issue of Rs.32.37crs.

-Alembic Limited has informed the Exchange that the company has despatched the Offer Document and Composite application form to all the shareholders on December 22, 2003. The Rights Issue is going to open on December 30, 2003, the last date for receiving requests for split forms is January 13, 2004 and the Rights Issue will close on January 28, 2004.

-The comnpany raised Rs 10 crore by placing 90-day commercial paper (CP) at 4.85 per cent with a mutual fund on March 8th.

-Alembic signs MoU with Xechem International

2005

- Launches a no-calorie sugar substitute, `Zero', on February 2, 2005.

2006
-Company has splits its Face value of Shares from Rs 10 to Rs 2

2008

- Alembic Ltd has informed that the Company has acquired API manufacturing unit of Nirayu Pvt Ltd. situated at Panelav, P.O. Tajpura, Taluka Halol, Dist. Panchmahals, Gujarat.

2009

-Alembic has recommended dividend at 20%

2010

-Mr. Milin Mehta has been appointed as additional Independent Director of the company.

2011

-Mr. Ashok Tulankar has been appointed as Vice President - Production as Additional Director & Whole-Time Director on the Board of the Company

2012

-Mr. Chandrashekhar P. Buch has been appointed as an Additional - Non-Executive Independent Director of the Company

2013
-Alembic Ltd has allotted 13,35,15,914 Bonus Shares in the ratio of 1:1.
-Alembic Ltd has appointed Mr. R. C. Saxena, as Additional Non-Executive Independent Director.
-The Board has recommended a dividend of Re. 0.20 (10%) per Equity Share of Rs. 2 each
-Alembic has announces Bonus in the Ratio of 1:1

2014
-Alembic Ltd has recommended a dividend of Re. 0.15/- (7.5%) per Equity Share of Rs. 2 each.

2018
-"HGS Wins NASSCOM Customer Service Excellence Award 2018 in Transformation Category".

2020
-Alembic gets USFDA nod for generic ophthalmic solution.

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article